News
Bristol Myers Squibb, BioNTech ink pact to co-develop, co-commercialize investigational bispecific antibody for multiple solid tumor types
Princeton: BioNTech SE and Bristol Myers Squibb have announced that the companies have entered into an agreement for the global co-development and co-commercialization of
Bristol Myers inks $11B BioNTech deal to join bispecific gold rush, leaping ahead of Merck and Pfizer
Bristol Myers Squibb is paying BioNTech $3.5 billion to board the PD-1/L1xVEGF-A bandwagon. The deal, which features up to $7.6 billion in milestones, gives BMS a 50% stake in one of the leading candidates in the hottest area of immuno-oncology.
BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...
BioNTech SE's $11.1B oncology move signals potential, but clinical hurdles remain. Click for my look at the BNTX deal with ...
Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.
Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer ...
BioNTech SE and BMS have partnered for the global co-development and co-commercialization of BNT327 across numerous solid ...
By Michael Erman and Ludwig Burger (Reuters) -Bristol Myers Squibb will pay $1.5 billion upfront to partner with Germany's ...
Bristol-Myers Squibb Co. will pay BioNTech SE as much as $11.1 billion to license a next-generation cancer drug, as ...
In the assessment of 12-month price targets, analysts unveil insights for BioNTech, presenting an average target of $138.7, a ...
Sortera Bio, a Cambridge biotech based on IP developed at the MRC Laboratory of Molecular Biology, has attracted big hitting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback